GSK shareholders approve asset swap deal with Novartis

LONDON, Dec 18 (Reuters) - Shareholders in British drugmaker GlaxoSmithKline have approved a planned deal with Switzerland's Novartis, which will see the two pharmaceutical groups trade more than $20 billion of assets.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.